RECURRENT NON SMALL CELL LUNG CANCER
Clinical trials for RECURRENT NON SMALL CELL LUNG CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT NON SMALL CELL LUNG CANCER trials appear
Sign up with your email to follow new studies for RECURRENT NON SMALL CELL LUNG CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug duo shows promise against lung cancer brain spread
Disease control CompletedThis study tested two targeted drugs, amivantamab and lazertinib, in 43 people with a specific type of lung cancer (EGFR-mutant) that had spread to the brain or spinal cord lining and was getting worse despite prior treatments. The goal was to see if the combination could shrink …
Matched conditions: RECURRENT NON SMALL CELL LUNG CANCER
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 17, 2026 03:19 UTC
-
New combo therapy tested for hard-to-treat lung cancer
Disease control CompletedThis early-stage study tested a new drug called ONO-7475 combined with the standard drug osimertinib in 78 people with advanced EGFR-mutant non-small cell lung cancer that could not be treated with radiation. The main goal was to check safety and find the right dose. Researchers …
Matched conditions: RECURRENT NON SMALL CELL LUNG CANCER
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 05, 2026 11:56 UTC